Last reviewed · How we verify
NCT04814771
Mass Balance Study of TS-142 in Healthy Adult Subjects.
Phase 1 trial testing [14C] TS-142 in Healthy Male Subjects in 6 participants. Completed in 19 May 2021.
19 May 2021
Quick facts
| Lead sponsor | Taisho Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 6 |
| Start date | 19 April 2021 |
| Primary completion | 19 May 2021 |
| Estimated completion | 19 May 2021 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- [14C] TS-142 — full drug profile →
Conditions studied
- Healthy Male Subjects — all drugs for Healthy Male Subjects →
Sponsor
Taisho Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 20 to 39, male only, with Healthy Male Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of TS-142 after single oral dose of \[14C\] TS-142 in Japanese healthy male subjects. To assess the safety of single oral dose of \[14C\] TS-142 in Japanese healthy male subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04814771
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Male Subjects
Currently open trials in the same condition.
- NCT07340476 — A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects · Phase 1 · active not recruiting
Other Taisho Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07285291 — A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders · Phase 3 · recruiting
- NCT07231029 — A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment · Phase 1 · recruiting
- NCT07285304 — A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis · Phase 3 · recruiting
- NCT07084961 — A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects · Phase 1 · completed
- NCT06849778 — An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04814771 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taisho Pharmaceutical Co., Ltd.
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04814771.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing